Journal of Molecular and Cellular Cardiology
Volume 47, Issue 2 , Pages 177-179 , August 2009

C-reactive protein: A multipronged assailant onendothelium-dependent vasodilation

  • Brandon T. Larsen

      Affiliations

    • Department of Pharmacology and Toxicology, Medical College of Wisconsin, USA
    • Department of Medicine, Medical College of Wisconsin, USA
    • ,
  • David D. Gutterman

      Affiliations

    • Department of Pharmacology and Toxicology, Medical College of Wisconsin, USA
    • Department of Medicine, Medical College of Wisconsin, USA
    • Cardiovascular Center, Medical College of Wisconsin, USA
    • Veterans Administration Medical Center, Milwaukee, Wisconsin, USA
    • Corresponding Author InformationCorresponding author. Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA. Tel.: +1 414 456 8495; fax: +1 414 456 6560.

Received 11 May 2009 ,Accepted 12 May 2009.

References 

  1. Gonzalez MA, Selwyn AP. Endothelial function, inflammation, and prognosis in cardiovascular disease. Am. J. Med. 2003;115(Suppl 8A):99S–106S
  2. Ridker PM. Connecting the role of C-reactive protein and statins in cardiovascular disease. Clin. Cardiol. 2003;26:III39–III44
  3. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 2008;359:2195–2207
  4. Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis?. Hypertension. 2004;44:6–11
  5. Qamirani E, Ren Y, Kuo L, Hein TW. C-reactive protein inhibits endothelium-dependent NO-mediated dilation in coronary arterioles by activating p38 kinase and NAD(P)H oxidase. Arterioscler. Thromb. Vasc. Biol. 2005;25:995–1001
  6. Grad E, Golomb M, Mor-Yosef I, Koroukhov N, Lotan C, Edelman ER, et al. Transgenic expression of human C-reactive protein suppresses endothelial nitric oxide synthase expression and bioactivity after vascular injury. Am. J. Physiol. Heart Circ. Physiol. 2007;293:H489–H495
  7. Lubos E, Handy DE, Loscalzo J. Role of oxidative stress and nitric oxide in atherothrombosis. Front. Biosci. 2008;13:5323–5344
  8. Goldstein S, Czapski G. The reaction of NO with O2- and HO2.: a pulse radiolysis study. Free Radic. Biol. Med. 1995;19:505–510
  9. Boulden BM, Widder JD, Allen JC, Smith DA, Al-Baldawi RN, Harrison DG, et al. Early determinants of H2O2-induced endothelial dysfunction. Free Radic. Biol. Med. 2006;41:810–817
  10. Landino LM, Crews BC, Timmons MD, Morrow JD, Marnett LJ. Peroxynitrite, the coupling product of nitric oxide and superoxide, activates prostaglandin biosynthesis. Proc. Natl. Acad. Sci. U. S. A. 1996;93:15069–15074
  11. Upmacis RK, Deeb RS, Hajjar DP. Regulation of prostaglandin H2 synthase activity by nitrogen oxides. Biochemistry. 1999;38:12505–12513
  12. Upmacis RK, Deeb RS, Hajjar DP. Oxidative alterations of cyclooxygenase during atherogenesis. Prostaglandins Other Lipid. Mediat. 2006;80:1–14
  13. Wu KK, Liou JY. Cellular and molecular biology of prostacyclin synthase. Biochem. Biophys. Res. Commun. 2005;338:45–52
  14. Zou M, Yesilkaya A, Ullrich V. Peroxynitrite inactivates prostacyclin synthase by heme-thiolate-catalyzed tyrosine nitration. Drug Metab. Rev. 1999;31:343–349
  15. Zou MH, Leist M, Ullrich V. Selective nitration of prostacyclin synthase and defective vasorelaxation in atherosclerotic bovine coronary arteries. Am. J. Pathol. 1999;154:1359–1365
  16. Peluffo G, Radi R. Biochemistry of protein tyrosine nitration in cardiovascular pathology. Cardiovasc. Res. 2007;75:291–302
  17. Fang J, Zhong L, Zhao R, Holmgren A. Ebselen: a thioredoxin reductase-dependent catalyst for alpha-tocopherol quinone reduction. Toxicol. Appl. Pharmacol. 2005;207:103–109
  18. Kuo L, Chilian WM, Davis MJ. Interaction of pressure- and flow-induced responses in porcine coronary resistance vessels. Am. J. Physiol. 1991;261:H1706–H1715
  19. Miura H, Wachtel RE, Liu Y, Loberiza FR, Saito T, Miura M, et al. Flow-induced dilation of human coronary arterioles: important role of Ca(2+)-activated K(+) channels. Circulation. 2001;103:1992–1998
  20. Kuo L, Davis MJ, Cannon MS, Chilian WM. Pathophysiological consequences of atherosclerosis extend into the coronary microcirculation. Restoration of endothelium-dependent responses by l-arginine. Circ. Res. 1992;70:465–476
  21. Feletou M, Vanhoutte PM. Endothelium-derived hyperpolarizing factor. Where are we now?. Arterioscler. Thromb. Vasc. Biol. 2006;
  22. Brzezinska AK, Gebremedhin D, Chilian WM, Kalyanaraman B, Elliott SJ. Peroxynitrite reversibly inhibits Ca(2+)-activated K(+) channels in rat cerebral artery smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol. 2000;278:H1883–H1890
  23. Liu Y, Terata K, Chai Q, Li H, Kleinman LH, Gutterman DD. Peroxynitrite inhibits Ca2+-activated K+ channel activity in smooth muscle of human coronary arterioles. Circ. Res. 2002;91:1070–1076
  24. Larsen BT, Bubolz AH, Mendoza SA, Pritchard KA, Gutterman DD. Bradykinin-induced dilation of human coronary arterioles requires NADPH oxidase-derived reactive oxygen species. Arterioscler. Thromb. Vasc. Biol. 2009;29:739–745
  25. Liu Y, Zhao H, Li H, Kalyanaraman B, Nicolosi AC, Gutterman DD. Mitochondrial sources of H2O2 generation play a key role in flow-mediated dilation in human coronary resistance arteries. Circ. Res. 2003;93:573–580
  26. Miura H, Bosnjak JJ, Ning G, Saito T, Miura M, Gutterman DD. Role for hydrogen peroxide in flow-induced dilation of human coronary arterioles. Circ. Res. 2003;92:e31–e40
  27. Larsen BT, Gutterman DD, Sato A, Toyama K, Campbell WB, Zeldin DC, et al. Hydrogen peroxide inhibits cytochrome p450 epoxygenases: interaction between two endothelium-derived hyperpolarizing factors. Circ. Res. 2008;102:59–67

PII: S0022-2828(09)00189-8

doi: 10.1016/j.yjmcc.2009.05.001

Journal of Molecular and Cellular Cardiology
Volume 47, Issue 2 , Pages 177-179 , August 2009

Article Tools